MOTS-c is not currently offered by telos rx, and there is no confirmed timeline for that to change. This article explains, honestly and without speculation, what would actually need to happen before a peptide like MOTS-c could become part of a real compounding program.
MOTS-c is not part of the telos rx compounding program, and no date should be assumed for that to change. telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin as compounded protocols today.
Why this question comes up so often
People who have researched MOTS-c and understood the biology reasonably ask a fair follow-up question: what is actually standing in the way. It is a better question than simply asking for a date, because it gets at the real mechanics rather than a guess.
This article breaks that question into its real components, rather than offering a vague answer about regulation in general. telos rx does not currently offer MOTS-c, and you can read more about its current status on the MOTS-c page.
Regulatory clarity, the first requirement
A 2026 review by the FDA's Pharmacy Compounding Advisory Committee produced non-binding recommendations touching several research peptides, MOTS-c included. That was a meaningful step, but it was explicitly non-binding, meaning it did not itself authorize compounding pharmacies to prepare and dispense MOTS-c.
A clearer, binding regulatory determination would be the single biggest factor that could change MOTS-c's status. Until that happens, any pharmacy compounding it would be operating in a legal gray area telos rx is not willing to enter.
For background on how the FDA regulates compounding more broadly, see the FDA overview of drug compounding.
Key takeaway: A non-binding committee recommendation is a step in a process, not a green light. Clearer, binding regulatory guidance is the single biggest thing that could change MOTS-c's status.
A verifiable, trustworthy supply chain
Even with clearer regulation, a compounding pharmacy needs a dependable source of pharmaceutical-grade raw material it can verify batch by batch. MOTS-c today is mostly available through research-chemical suppliers with no pharmaceutical quality standards behind them.
Building or identifying a supply chain that meets the standard telos rx applies to everything it compounds is a separate piece of work. It would need to happen regardless of what the FDA ultimately decides on the regulatory question.
Purity, consistency, and traceability all matter here. A peptide sold as a research chemical, with no accountability for what is actually in the vial, does not meet that bar no matter how promising the underlying biology looks.
Stronger human evidence
Most published MOTS-c research to date has been done in cells or animals. Confirmed, well-controlled human studies establishing a specific effect, an appropriate dose, and a safety profile are still comparatively limited.
telos rx applies its own clinical review before adding a peptide to its program, separate from the regulatory question. A thicker, more consistent body of human evidence would materially strengthen the case for adding MOTS-c, even once the regulatory and supply questions are settled.
This is not a criticism of the science as it exists today. It is simply an honest description of where the evidence currently sits relative to what a responsible clinical program requires.
An internal program decision
Even with regulatory clarity, a verified supply chain, and stronger human evidence, telos rx would still need to make its own decision. That final decision does not happen automatically once the other pieces fall into place.
Compounded medications, including the ones telos rx already offers, are not FDA-approved to begin with. Adding a new peptide is always a deliberate, internal decision layered on top of that baseline reality, not something that happens by default.
No internal date has been set for MOTS-c, and this article will not speculate about one. If a decision is made, the MOTS-c page is where it would be reflected.
How this compares to a peptide that already cleared the bar
It helps to look at BPC-157, which telos rx does compound today, as a point of comparison. BPC-157 has a longer research history, a supply chain telos rx has been able to verify, and an internal review that concluded it could be offered responsibly through a real clinical intake.
That does not mean BPC-157 is FDA-approved. It is not, and no compounded medication telos rx offers is. It means BPC-157 cleared the specific, internal bar telos rx applies before adding anything to its program, the same bar MOTS-c has not yet cleared.
Looking at that comparison is useful precisely because it shows the bar is real and consistently applied, not an arbitrary excuse specific to MOTS-c.
Why telos rx does not set public deadlines
It would be easier, from a marketing standpoint, to give MOTS-c a projected launch window. telos rx deliberately does not do that, because a projected date creates an expectation that regulatory and supply chain realities may not support.
Patients who plan around an unofficial date and then watch it slip tend to lose trust, reasonably so. Avoiding that outcome matters more to telos rx than the short-term benefit of a hopeful-sounding announcement.
This is also why this article resists the temptation to guess at a range, even a wide one. A guess dressed up as an estimate is still a guess, and it does not serve you any better than no answer at all.
What this does not mean
None of this should be read as a promise that MOTS-c is coming at some point down the line. It is entirely possible the regulatory picture, the supply chain, or the evidence base never reaches a point where telos rx adds it. That is a real, honest possibility, not a hedge.
It is also possible the picture changes meaningfully within a reasonable window. Neither outcome is predictable from where things stand today, and treating either as certain would be misleading.
What you can do meanwhile
If you are specifically interested in MOTS-c, the most useful thing you can do is keep following the primary research rather than vendor marketing. Check the MOTS-c page periodically for any actual program update instead.
Reading original studies, tracked against a database like PubMed, will give you a far more accurate picture than a forum or a product page ever could. The NIH's general guidance on evaluating unregulated health products, in using dietary supplements wisely, is a useful companion habit even outside the supplement category specifically.
If your underlying interest is broader, such as cellular energy, metabolism, or general wellness, telos rx already offers a compounded NAD+ nasal spray built around a related biological pathway. It comes with a real clinical intake, unlike an unregulated online purchase. If that fits, you can start an intake for NAD+ nasal spray today.
How other peptides have moved from review to availability
Looking at how telos rx has handled other peptides over time is instructive, even without promising the same path for MOTS-c. A peptide typically moves from under-review status to available only after three things line up: regulatory clarity, a verified supply source, and a satisfied internal clinical review. They tend to line up together, not one at a time in isolation.
Sometimes one piece lags behind the others for a long stretch. A peptide might have strong human research and a workable supply chain but sit waiting on regulatory clarity, or the reverse. There is no fixed order and no confirmed pace, which is part of why any specific prediction about MOTS-c would be irresponsible.
What is consistent is that telos rx does not add anything to its compounding program until all three pieces are satisfied at once. That consistency is the actual policy, even though it can feel unsatisfying if you are waiting on a specific peptide.
Questions worth asking a vendor selling MOTS-c today
If you encounter a vendor selling MOTS-c for personal use, a few direct questions tend to reveal a lot. Ask whether the product has been independently tested for purity, and ask to see that documentation rather than taking a claim at face value.
Ask whether the seller is a licensed pharmacy or a research-chemical supplier, since those are legally distinct categories with very different obligations. Ask what recourse exists if the product does not match its labeling.
In most cases, a research-chemical vendor cannot answer these questions the way a licensed compounding pharmacy can. That gap is exactly why telos rx does not operate in that space for peptides still under review.
Frequently Asked Questions
What is the single biggest obstacle to MOTS-c becoming available?
Clearer, binding regulatory guidance is the most significant factor. The 2026 committee review produced only a non-binding recommendation, which did not authorize compounding on its own.
Does telos rx have a target date for adding MOTS-c?
No. There is no confirmed timeline, and this article deliberately does not speculate about one.
Is the supply chain really a separate issue from regulation?
Yes. Even with clear regulatory approval, telos rx would still need a verifiable, pharmaceutical-grade source of MOTS-c, which is a distinct question from whether compounding it is legally permitted.
Could telos rx decide not to add MOTS-c even if regulation changes?
Yes. Regulatory clarity would remove one obstacle, but telos rx still applies its own internal review before adding any peptide to its program.
Is MOTS-c FDA-approved right now?
No. Compounded medications generally are not FDA-approved, and MOTS-c is also not currently offered by telos rx in any form.
What can I do if I want a compounded peptide protocol today?
telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each with a real clinical intake process.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved. MOTS-c is not currently offered by telos rx in any form. This article is general information, not medical advice, and does not replace guidance from your own provider.
Want an available protocol today? Learn about NAD+ nasal spray or explore the full telos rx lineup.